€3.21
1.35%
L&S, Jun 28, 10:54 pm CET
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Valneva Share price

€3.18
-0.78 19.72% 1M
-1.64 34.02% 6M
-1.54 32.54% YTD
-3.64 53.33% 1Y
-7.55 70.33% 3Y
+0.01 0.28% 5Y
-2.12 39.92% 10Y
Paris, Closing price Fri, Jun 28 2024
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Key figures

Market capitalization €443.06m
Enterprise Value €478.09m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.13
P/S ratio (TTM) P/S ratio 2.90
P/B ratio (TTM) P/B ratio 2.34
Sales growth (TTM) Sales growth -58.99%
Turnover (TTM) Turnover €152.96m
EBIT (operating result TTM) EBIT €-109.09m
Free cash flow (TTM) Free cash flow €-236.26m
Cash position €176.64m
EPS (TTM) EPS €-0.18
P/E ratio expected 25.47
P/S ratio expected 2.33
EV/Sales expected 2.52
Show more

Is Valneva a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Valneva Share analysis

Unlock scores for free

Analyst opinions

10 Analysts have issued a Valneva forecast:

9x Buy
90%
1x Hold
10%

Analyst opinions

10 Analysts have issued a Valneva forecast:

Buy
90%
Hold
10%

Financial data from Valneva

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
153 153
59% 59%
100%
- Direct costs 103 103
69% 69%
67%
55 55
31% 31%
36%
- Selling and administrative expenses 101 101
106% 106%
66%
- Research and development costs 59 59
40% 40%
39%
- -
-
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT -109 -109
13% 13%
-71%
Net profit -24 -24
82% 82%
-16%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the Valneva share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Company profile

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Head office France
CEO Thomas Lingelbach
Employees 676
Founded 1999
Website www.valneva.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now